Skip to main content

Table 2 Factors influencing LRFS, EFS and OS (Cox proportional Hazard Model)

From: Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution

Analysis using locoregional recurrence free survival (type 1)

Factors

Univariate analysis

Multivariate analysis

 

HR

95% CI

P value

HR

95% CI

P value

Lymph node involvement: no vs yes

0.794

0.221 to 2.846

0.717

-

-

-

Tumour: pT1-2 vs pT3-4

0.273

0.095 to 0.787

0.016

0.326

0.11 to 0.963

0.043

SBR grade: 1-2 vs 3

0.692

0.232 to 2.066

0.509

-

-

-

ER status: positive vs negative

0.359

0.125 to 1.036

0.058

0.387

0.13 to 1.157

0.079

Age: ≥ 40 vs < 40

1.288

0.359 to 4.618

0.697

-

-

-

Regimen: anthracycline vs CMF

0.454

0.157 to 1.308

0.143

0.347

0.114 to 1.053

0.062

Number of cycles of CT delivered concurrently with RT: ≥ 2 vs 1

0.466

0.223 to 1.987

0.439

0.587

0.244 to 1.414

0.235

Analysis using event free survival

 

Univariate analysis

Multivariate analysis

 

HR

95% CI

P value

HR

95% CI

P value

Lymph node involvement: no vs yes

0.406

0.216 to 0.766

0.004

0.397

0.216 to 0.779

0.006

Tumour: pT1-2 vs pT3-4

0.552

0.356 to 0.855

0.007

0.624

0.392 to 0.993

0.047

SBR grade: 1-2 vs 3

0.801

0.508 to 1.265

0.341

0.971

0.598 to 1.576

0.906

ER status: positive vs negative

0.674

0.438 to 1.038

0.058

0.64

0.404 to 1.015

0.058

Age: ≥ 40 vs < 40

1.183

0.717 to 1.951

0.511

-

-

-

Regimen: anthracycline vs CMF

0.665

0.435 to 1.016

0.057

0.558

0.354 to 0.879

0.012

Number of cycles of CT delivered concurrently with RT: ≥ 2 vs 1

0.696

0.445 to 1.089

0.11

0.625

0.39 to 1.002

0.051

Analysis using overall survival

 

Univariate analysis

Multivariate analysis

 

HR

95% CI

P value

HR

95% CI

P value

Lymph node involvement: no vs yes

0.298

0.137 to 0.651

0.002

0.317

0.144 to 0.697

0.004

Tumour: pT1-2 vs pT3-4

0.619

0.381 to 1.005

0.052

0.719

0.429 to 1.208

0.213

SBR grade: 1-2 vs 3

0.694

0.427 to 1.130

0.142

0.781

0.466 to 1.309

0.347

ER status: positive vs negative

0.737

0.458 to 1.186

0.208

0.714

0.429 to 1.189

0.196

Age: ≥ 40 vs < 40

1.260

0.723 to 2.197

0.414

-

-

-

Regimen: anthracycline vs CMF

0.708

0.445 to 1.128

0.143

0.603

0.367 to 0.99

0.046

Number of cycles of CT delivered concurrently with RT: ≥ 2 vs 1

0.768

0.468 to 1.261

0.297

0.713

0.423 to 1.201

0.203

  1. Abbreviations: HR = hazard ratio; CI = confidence interval; SBR = Scarf-Bloom-Richardson; ER = estrogen receptor; CT = chemotherapy; RT = radiotherapy
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us